Sarah Bos

95 Efficacy of pro- and anticoagulant strategies in plasma 6 Table 1. Patient characteristics OLT (n=20) P-HEP (n=20) PPPD (n=20) Controls (n=42) Age, years 53 [41-59] 60 [46-77] 65 [60-73] 29 [27-40] Sex, male/female 12/8 9/11 12/8 20/16 Cirrhosis, n (%) 20 (100) - 1 (5) - Laparoscopic, n (%) - 6 (30) - - Hemoglobin, g/dl 122 [104-128] 133 [123-139] 126 [118-136] Platelet count, G/L 134 [69-163] 238 [199-299] 237 [208-312] WBC count, G/L 5 [4-7.0] 7 [5-8] 7 [6-9] Sodium, mmol/L 136 [132-140] 140 [137-141] 139 [136-140] Creatinin, umol/L 72 [55-91] 68 [57-86] 72 [58-78] Alkaline phosphatase, U/L 177 [108-278] 115 [74-153] 149 [100-349] AST, U/L 65 [46-131] 25 [21-36] 30 [23-68] GGT, U/L 100 [57-178] 52 [31-129] 127 [37-481] Bilirubin, μ mol/L 36 [21-71] 8 [6-10] 15 [10-21] Length of surgery, min 335 [271-377] 263 [180-362] 406 [343-530] - Estimated blood loss, ml 3236 [2205-4000] 625 [263-1825] 145 [110-1163] - RBC transfusion, ml 554 [271-1190] 447 [0] 570 [0] - FFP transfusion, ml 1796 [1348-2650] 600 [0] - - Platelet transfusion, ml 315 [304-576] - - - Length of hospital stay, days 13 [10-16] 8 [6-10] 14 [9-18] - Thromboprophylaxis, n (%) 18 (90)* 18 (90) * 20 (100) * - Postoperative VTE, n (%) 1 (5) 0 (0) 1 (5) Surgical indications Metastatic disease, n (%) - 7 (35) Hepatocellular carcinoma, n (%) - 4 (20) Neuroendocrine tumor, n (%) - 1 (5) Cholangiocarcinoma, n (%) - 1 (5) Epitelioid hemangioendothelioma, n (%) 1 (5) Benign tumor, n (%) - 6 (30) Pancreatic carcinoma, n (%) 12 (60) Ampullary adenoma, n (%) 4 (20) Side branch IPMN, n (%) 1 (5) Common bile duct stricture, n (%) 2 (10) Insulinoma, n (%) 1 (5) OLT, orthotopic liver transplantation; PPPD, pylorus-preserving pancreaticoduodenectomy; P-HEP, partial hepatectomy; WBC, white blood cell; RBC, red blood cell; FFP fresh frozen plasma; numbers are represented as median [IQR], mean [SD] or numbers (%).* thromboprophylaxis was started at day 1, the first postoperative sample was drawn before the first dose, whereas other samples were drawn just before the next dose.